In a study with patient in oral anticoagulation for AF, a high-sensitivity interleukin-6 (hsIL6) was a predictor of long-term cardiovascular events (HR 1.97, p = 0.002) and all-cause mortality (HR 2.48, p < 0.001) [37]; and adding hsIL6 to the clinical risk scores (CHADS2 and CHA2DS2-VASc) improved the discrimination index value for prediction of long-term cardiovascular events and death [37]. This evidence concerns the gene IL6 and atrial fibrillation.